References
- OtrembaIWilczyńskiKSzewieczekJDelirium in the geriatric unit: proton-pump inhibitors and other risk factorsClin Interv Aging20161139740527103793
- FujiiSTanimukaiHKashiwagiYComparison and analysis of delirium induced by histamine h(2) receptor antagonists and proton pump inhibitors in cancer patientsCase Rep Oncol2012540941222949902
- AnderssonTMinersJOVeroneseMEBirkettDJDiazepam metabolism by human liver microsomes is mediated by both S-mephenytoin hydroxy-lase and CYP3A isoformsBr J Clin Pharmacol1994381311377981013
- LiWZengSYuLSZhouQPharmacokinetic drug interaction profile of omeprazole with adverse consequences and clinical risk managementTher Clin Risk Manag2013925927123745048
- ZhouQYanXFZhangZMPanWSZengSRational prescription of drugs within similar therapeutic or structural class for gastrointestinal disease treatment: drug metabolism and its related interactionsWorld J Gastroenterol2007135618562817948937
- GjestadCWestinAASkogvollESpigsetOEffect of proton pump inhibitors on the serum concentrations of the selective serotonin reuptake inhibitors citalopram, escitalopram, and sertralineTher Drug Monit2015379097.324887634
References
- EarnestDLRobinsonMTreatment advances in acid secretory disorders: the promise of rapid symptom relief with disease resolutionAm J Gastroenterol199994S17S2410565605
- WelageLSBerardiRREvaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseasesJ Am Pharm Assoc (Wash)200040526210665250
- HuangJQHuntRHPharmacological and pharmacodynamic essentials of H(2)-receptor antagonists and proton pump inhibitors for the practising physicianBest Pract Res Clin Gastroenterol20011535537011403532
- RanePPGuhaSChatterjeeSAparasuRRPrevalence and predictors of non-evidence based proton pump inhibitor use among elderly nursing home residents in the USRes Social Adm Pharm Epub201638
- SchoenfeldAJGradyDAdverse Effects Associated With Proton Pump InhibitorsJAMA Intern Med201617617217426751904